Xatmep (Methotrexate) Patent Expiration, LOE Window & CMS Spending

Xatmep (Methotrexate) by Azurity: FDA Orange Book LOE 2033-01-02, 9 AB generics, $3.2M 2024 CMS Part D & Medicaid spend, and 6 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorAzurity
FDA Application & PathwayN208400 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2033-01-02
Orange Book Patents (*PED Extensions)7 patents (0 *PED)
Active AB-Rated Generic Competitors9
2024 CMS Total Public Spend$3.2M
2024 Medicare Part D Spend$246K
2024 Medicaid Spend$3.0M
Reported Wholesale Price Change (CA SB 17)6 WAC filings (max 24.3% 2-yr change)